Common Contracts
2 similar null contracts
Licence agreement concerning inclusion of doctoralFebruary 3rd, 2023
Xinyu Di was born on Nov 14th, 1992 in the town of Changjiang, Rugao, China. After graduating from Rugao Senior High School in 2010, he got admitted to the major of Pharmacy at China Pharmaceutical University (CPU) in Nanjing. In 2014, he obtained his bachelor's degree and continued in the same university his master’s study in pharmacokinetics. During his master's study, he focused on preclinical pharmacokinetic studies of several small molecules. In October 2017, he started his PhD project under the supervision of Prof. Dr. Thomas Hankemeier, Dr. Isabelle Kohler and Dr. Elke H.J. Krekels at Leiden Academic Centre for Drug Research (LACDR). Between 2017 and 2022, he developed metabolomics platforms for the endocannabinoid system (ECS). With these platforms, he looked into the role of ECS in exercise and cardiometabolic health, explored the role of several enzymes in the ECS and evaluated drugs targeting these enzymes. Since February 2022, he has been working as a postdoc in the group o
Licence agreement concerning inclusion of doctoralFebruary 3rd, 2023
Xinyu Di was born on Nov 14th, 1992 in the town of Changjiang, Rugao, China. After graduating from Rugao Senior High School in 2010, he got admitted to the major of Pharmacy at China Pharmaceutical University (CPU) in Nanjing. In 2014, he obtained his bachelor's degree and continued in the same university his master’s study in pharmacokinetics. During his master's study, he focused on preclinical pharmacokinetic studies of several small molecules. In October 2017, he started his PhD project under the supervision of Prof. Dr. Thomas Hankemeier, Dr. Isabelle Kohler and Dr. Elke H.J. Krekels at Leiden Academic Centre for Drug Research (LACDR). Between 2017 and 2022, he developed metabolomics platforms for the endocannabinoid system (ECS). With these platforms, he looked into the role of ECS in exercise and cardiometabolic health, explored the role of several enzymes in the ECS and evaluated drugs targeting these enzymes. Since February 2022, he has been working as a postdoc in the group o
